David Bernstein

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Péter Ferenci, David Bernstein, Jacob Lalezari et al. · New England Journal of Medicine · 2014 · 695 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

David R. Nelson, James N. Cooper, Jacob Lalezari et al. · Hepatology · 2015 · 689 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

Eric Lawitz, Jay Lalezari, Tarek Hassanein et al. · The Lancet Infectious Diseases · 2013 · 328 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy

Douglas K. Rex, Raj Bhandari, Taddese Desta et al. · Gastrointestinal Endoscopy · 2018 · 304 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Antituberculosis Drug–induced Hepatotoxicity: The Role of Hepatitis C Virus and the Human Immunodeficiency Virus

Jaime Ungo, Denis Jones, David Ashkin et al. · American Journal of Respiratory and Critical Care Medicine · 1998 · 292 citations

Medicine, Infectious Diseases, Pharmacology +9